Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
Samir K. Gupta(Indiana University School of Medicine), Ellen Koenig(Instituto Dermatológico y Cirugía de Piel "Dr. Huberto Bogaert Díaz"), Cheryl McDonald(Texas Center for Infectious Disease), Paul Benson, Hadas Dvory‐Sobol(Gilead Sciences (United States)), Mezgebe Berhe, Laurie A. VanderVeen(Gilead Sciences (United States)), Shanyu Liu(Chinese Academy of Sciences), Jared M. Baeten(University of Washington), Moti Ramgopal(Midway University), James J. Sims(University of California, Riverside), Peter Ruane, Gordon Crofoot(Clinical Research Organization), Anita Scribner(Special Health Resources for Texas), Martin S. Rhee(Gilead Sciences (United States)), William E Sanchez
Cited by 107
Related Papers
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women
|New England Journal of Medicine|2012|3.3k
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
|The Lancet|2010|958
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
|Gastroenterology|2015|799
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
|New England Journal of Medicine|2016|768
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
|New England Journal of Medicine|2017|565